The clinical outcomes of the AAVIATE study (NCT04514653) is discussed in this touchOPHTHALMOLOGY interview with Prof. Arshad Khanani (Sierra Eye Associates, Reno, NV, USA). RGX-314 is being developed as a potential one-time treatment for neovascular AMD as current anti-VEGF therapies require life-long intraocular injections to maintain efficacy. Due to the burden of treatment, patients often experience a decline in vision with reduced frequency of treatment over time.
The presentation entitled ‘Suprachoroidal Delivery of RGX-314 Gene Therapy for Neovascular AMD: The Phase II AAVIATE™ Study’ was presented at the The Association for Research in Vision and Ophthalmology, May 01-04, 2022.
- What are the aims and methodology of the AAVIATE study?
- What have the initial findings taught us about the efficacy, safety and tolerability of RGX-314?
- Which patients are most likely to benefit from this treatment?
Disclosures: Arshad Khanani is a consultant for Regenxbio and discloses grant/research Support from Regenxbio.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Shanice Allen.
Share this Video
Related Videos In Macular Degeneration
Katerina Prokopiou, ARVO 2022: Therapeutic potential of omega-3 fatty acids supplementation in dry age-related macular degeneration and Stargardt Disease
The clinical outcomes of the MADEOS trial (NCT03297515) is discussed in this touchOPHTHALMOLOGY interview with Dr Katerina Prokopiou (University of Nicosia Medical School, Engomi, Cyprus). Currently, there is no effective treatment available that stops progression or improves vision in patients with dry age-related macular degeneration or Stargardt disease, the MADEOS trial assesses the therapeutic potential of […]
Katerina Prokopiou, ARVO 2022: Stargardt disease and dry age-related macular degeneration: omega-3 fatty acids supplementation
Stargardt disease is a rare genetic eye disease that happens when fatty material builds up on the macula. An overview of the rationale for the use of omega-3 fatty acids in patients with Stargardt disease and dry age-related macular degeneration are discussed in this touchOPHTHALMOLOGY interview with Dr Katerina Prokopiou (University of Nicosia Medical School, Engomi, […]
Arshad Khanani, ARVO 2022: RGX-314 gene therapy for neovascular age-related macular degeneration
An overview and the mechanism of action of RGX-314 is discussed in this touchOPHTHALMOLOGY interview with Prof. Arshad Khanani (Sierra Eye Associates, Reno, NV, USA) as well as the limitations of anti-VEGF therapy for neovascular AMD. The presentation entitled ‘Suprachoroidal Delivery of RGX-314 Gene Therapy for Neovascular AMD: The Phase II AAVIATE™ Study’ was presented […]
Journal articles and more to your inbox
Get the latest clinical insights from touchOPHTHALMOLOGYSign me up!